Pfizer (PFE) and BioNTech SE (BNTX) announced the U.S. Food and Drug Administration granted Emergency Use Authorization, or EUA, of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as the third 3-microgram dose in the three-dose primary series for children 6 months through 4 years of age. Children in this age group can receive a primary series consisting of two 3-microgram doses of the original Pfizer-BioNTech COVID-19 Vaccine followed by a third 3-microgram dose of the bivalent vaccine to complete the primary series. Vaccine doses can be delivered immediately upon receipt of a recommendation from the U.S. Centers for Disease Control and Prevention, the companies stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PFE:
- Two “Perfect 10” Healthcare Stocks to Beat the Market
- #SocialStocks: EU rules against Meta, despite attempts to settle
- Prometheus price target raised to $114 from $67 at Piper Sandler
- Pfizer: FDA accepts for priority review BLA for RSV vaccine candidate, RSVpreF
- Pfizer dismisses Moderna claim it copied COVID-19 shot, CNBC reports